Skip Nav Destination
Issues
1 July 2016
-
Cover Image
Cover Image
It has been long known that garlic has medicinal properties and may even reduce the risk of developing certain cancers including those of the gastrointestinal tract. The chemopreventive effects of garlic may be attributed to the anti-inflammatory properties of garlic's sulfur-containing constituents which include diallyl disulfide (DADS). When colorectal cancer cells were treated with DADS, NFkB nuclear localization and activity were diminished. Interestingly, this effect of DADS on NFkB suppression was found to be dependent on DADS inhibition of GSK-3β, a positive regulator of NFkB. The figure shown on the cover is the soft agar plate (100 mm) in which SW480 colon cancer cells were pre-treated with DADS (5 μM) plus GSK-3β activator LY294002 (10 μM) for 24 hrs. This simultaneous treatment with DADS (5 μM) and LY294002 (10 μM) abolished anti-tumorigenic effects of DADS, which suggests that this garlic component inactivates NFkB by largely inhibiting GSK-3β. See article by Saud and colleagues (beginning on page 607) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Commentary
Review: Molecular Pathogenesis of Premalignancy Series
Research Articles
Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis
Guosong Jiang; Amy D. Wu; Chao Huang; Jiayan Gu; Liping Zhang; Haishan Huang; Xin Liao; Jingxia Li; Dongyun Zhang; Xingruo Zeng; Honglei Jin; Haojie Huang; Chuanshu Huang
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.